z-logo
open-access-imgOpen Access
Lorlatinib in ALK- and ROS1-positive NSCLC: the future has a start
Author(s) -
Francesco Facchinetti,
Luc Friboulet
Publication year - 2018
Publication title -
translational lung cancer research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.474
H-Index - 41
eISSN - 2226-4477
pISSN - 2218-6751
DOI - 10.21037/tlcr.2018.02.04
Subject(s) - ros1 , medicine , lung cancer , cancer research , oncology , adenocarcinoma , cancer

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here